HC Wainwright & Co. Downgrades Calliditas Therapeutics to Neutral, Announces $39 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has downgraded Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral, with a new price target of $39.
May 28, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HC Wainwright & Co. has downgraded Calliditas Therapeutics from Buy to Neutral, with a new price target of $39. This downgrade may lead to a short-term negative impact on the stock price as investor sentiment adjusts.
The downgrade from Buy to Neutral by a reputable analyst firm like HC Wainwright & Co. typically signals a less optimistic outlook, which can lead to a decrease in investor confidence and a potential short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100